Baxter International Inc. Stock Xetra

Equities

BTL

US0718131099

Medical Equipment, Supplies & Distribution

Real-time Estimate Tradegate 09:27:45 2024-05-28 EDT 5-day change 1st Jan Change
31.46 EUR -46.49% Intraday chart for Baxter International Inc. 0.00% 0.00%

Financials

Sales 2024 * 15.11B 13.89B 20.58B Sales 2025 * 15.66B 14.4B 21.33B Capitalization 17.27B 15.88B 23.53B
Net income 2024 * 703M 646M 958M Net income 2025 * 950M 873M 1.29B EV / Sales 2024 * 1.79 x
Net Debt 2024 * 9.7B 8.92B 13.22B Net Debt 2025 * 8.8B 8.09B 11.99B EV / Sales 2025 * 1.67 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
15.1 x
Employees 60,000
Yield 2024 *
3.52%
Yield 2025 *
3.65%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
3 years
56.80
Extreme 56.8
78.20
5 years
56.80
Extreme 56.8
87.22
10 years
28.31
Extreme 28.305
87.22
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-09-30
Director of Finance/CFO 54 23-10-17
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-05
Director/Board Member 64 22-05-09
Director/Board Member 64 19-02-17
More insiders
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
33.9 USD
Average target price
46.07 USD
Spread / Average Target
+35.89%
Consensus